C-AHHAumbilical cord blood-derived MSCs, regenerative medicine, stem cell therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
To establish the efficacy and safety of CARTISTEM®, a combination product composed of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) formulated with a cross-linked sodium hyaluronate (HA) hydrogel, CARTISTEM® compared to the surgical comparator of debridement in Subjects with knee cartilage lesions and osteoarthritis. This trial is intended to provide evidence of the superiority of CARTISTEM® to reduce knee pain and improve knee function compared to debridement for Subjects with knee cartilage lesions and osteoarthritis at 2-years post-treatment. Additionally, this trial is intended to intended to explore whether CARTISTEM® may have disease-modifying effects on osteoarthritis progression through the use of semi-quantitative MRI assessment.
This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.
This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K\&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee - i.e., the more severely affected knee), and enroll in this study.
This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase I trial (NCT04037345 ) will be followed-up until 60 months.
This clinical trial is performed with patients with knee osteoarthritis who were radiologically diagnosed with Kellgren-Lawrence (K\&L) grade 2 or 3. Subjects who voluntarily signed consent form and met inclusion/exclusion criteria, were evaluated eligible and participated in this trial. Investigator selected knee to be evaluated (right or left) and administered investigational product to selected knee on Day 1. A total of 3 or 6 subjects will be enrolled in low-dose or mid-dose group each, and 6 subjects will be enrolled in high-dose group. The study used a dose escalation scheme (from low-dose to high-dose) to determine the maximum tolerated dose (MTD).
This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT03392467) will be followed-up until 60 months of corrected age
The purpose of this study is to assess whether cosmetic investigational product containing NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.
This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.
A long-term follow-up study to obtain safety and efficacy data in subjects who completed phase 1/2a clinical trial of NEUROSTEM® (NCT02054208), comparing NEUROSTEM and placebo groups for up to 36 months after the initial administration in patients suffering from Alzheimer's disease
PNEUMOSTEM® consists of ex vivo cultured allogeneic, unrelated, human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and it is intended for use as a cellular therapy product for prevention of Bronchopulmonary Dysplasia (BPD). This study is an open-label, single-center, dose escalation study to evaluate of safety and efficacy of PNEUMOSTEM® in premature infants at high risk for BPD.
This is a 5-year long-term follow-up study of open label, single-center, phase I clinical trial to evaluate the safety and efficacy of PNEUMOSTEM® in premature infants with bronchopulmonary dysplasia.
This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived mesenchymal stem cells) versus placebo via an Ommaya reservoir at 4 week intervals in patients with Alzheimer's disease.
This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT01828957) will be followed-up until 60 months of corrected age.
The objective of this study is to evaluate the efficacy and safety of a single intratracheal administration of Pneumostem® for treatment of Bronchopulmonary Dysplasia (BPD) in high-risk premature infants by comparing Pneumostem-treated group with a control group.
The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
This is a long term follow-up study to investigate the safety and efficacy of CARTISTEM®, human umbilical cord blood-derived mesenchymal stem cells, in repair of cartilage injury or defects, compared with microfracture. Subjects who participated in and completed the Phase III trial (NCT01041001) will be tracked until the 60 month post-treatment timepoint.
The umbilical cord blood stem cells break new ground in healing hard-to-cure diseases [Anchor] With the increasing number of the patients who suffer from the hard-to-cure diseases, various treatments have been tried for eliminating the cause. Recently, the "umbilical cord blood stem cells" are brought up to be the new solutions and give hope to the patients. Our next report has the details. [Reporter] The stem cells are basic cells for making about two hundred and sixty of body cells such as bones, bloods, and nerves. By duplicating themselves, the stem cells restore the damaged cells. Among them, especially, the umbilical cord blood stem cells are highly effective on curing the hard-to-cure diseases. Those cells, which have the functions to investigate and chase the specific cells, are from the cellular tissue of the umbilical cord. With this, it is possible to load the anti-cancer genes or healing substances so as to fight off the germs selectively. [Interview - Wo
[Anchor] With the increasing number of the patients who suffer from the hard-to-cure diseases, various treatments have been tried for eliminating the cause. Recently, the "umbilical cord blood stem cells" are brought up to be the new solutions and give hope to the patients. Our next report has the details. [Reporter] The stem cells are basic cells for making about two hundred and sixty of body cells such as bones, bloods, and nerves. By duplicating themselves, the stem cells restore the damaged cells. Among them, especially, the umbilical cord blood stem cells are highly effective on curing the hard-to-cure diseases. Those cells, which have the functions to investigate and chase the specific cells, are from the cellular tissue of the umbilical cord. With this, it is possible to load the anti-cancer genes or healing substances so as to fight off the germs selectively. [Interview - Won-il Oh, Director of Research of MEDIPOST] ~ The umbilical cord blo
The primary purpose of this study is to evaluate the safety and the tolerability of NEUROSTEM®-AD (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) and to assess the maximum tolerated dose (MTD). This study is also to investigate the efficacy of this study drug in patients with dementia of Alzheimer's type.
PNEUMOSTEM® is human umbilical cord blood derived mesenchymal stem cells and it is intended to treat premature infants with bronchopulmonary dysplasia. This study is to assess the safety and the efficacy of this study drug.
The purpose of the study is to assess and compare the safety and efficacy of the allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product (Cartistem®) to that of a microfracture treatment in patients with articular cartilage defect or injury.
The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and prevention of graft rejection and Graft-Versus-Host Disease after unrelated hematopoietic stem cell transplantation for children with acute leukemia.
MEDIPOST | Asia Bio Partnering Forum You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. $500 savings expire in: 00 Days 00 Hrs 00 Mins 00 Secs Singapore September 1–2, 2026 Marina Bay Sands Home home Get Involved expand_more Registration Options Company Presenta
%PDF-1.6 %���� 524 0 obj > endobj 556 0 obj >/Filter/FlateDecode/ID[ ]/Index[524 83]/Info 523 0 R/Length 132/Prev 4020117/Root 525 0 R/Size 607/Type/XRef/W[1 2 1]>>stream h�bbd``b`1 N@��Hp���@��$f����Dw H��)�� �g V ��":��$�U $X�A�m �/H�Ě���2 � �b7H4�a`bd� ���q$��.�A endstream endobj startxref 0 %%EOF 606 0 obj >stream h�b``�b``Z������ ̀� � l , � �ܚ�X��_��h���9r|�R}ы}t �(:V���ɩq������$�)���H ��xBc�� ���[%���pt��`F�F������q�(K0*i@u�T2 ´d@i�Y x����Q��F��!2 ��p4:���P�p��$A��&� w�K� �70�8pT0LePj���ཀI�!���� > endobj 526 0 obj >/ExtG … ~�]�r��{�?� ����I�x��g� 韛� �����>���a2 endstream endobj 284 0 obj >stream application/pdf Brochure-eng-251230 2026-04-29T11:02:42+09:00 2026-04-29T11:02:42+09:00 2026-04-29T11:02:22+09:00 Adobe Illustrator 30.3 (Macintosh) 256 64 JPEG /9j/4AAQSkZJRgABAgEAAAAAAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAAAAAAAAEA
AQAAAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f&
Speaker - BIO Asia–Taiwan 2026 --> --> July 15-19, 2026 TaiNEX, Taipei Registration search --> search --> ↵ About About BIO Asia–Taiwan Organizing Committee International Committee Post-event Report Contact us News Event Announcement Press Release Media Coverage Social Media Toolkit Programme Schedule at Glance 2026 Conference Overview 2026 Plenary Sessions 2026 Innovation Forum 2026 Investment Summit 2026 Regional Collaboration Forum 2026 Company Presentations 2026 Satellite Symposia Site Visit Program Social Events 2026 Company Presentations Partnering BIO Partnering™ at BIO Asia … r List For Attendees Registration Venue & Transportation Accommodation Visa Application Travel and Tourism Sponsorship Become a Sponsor 2026 Sponsor List speaker 2026 Company Presentation 2026 Company Presentation Home / speaker / Company Presentation / 2026 Company Presentation 2026 Company Presentation --> JENN CHIAN MACHINERY CO.,LTD. --> Copyright © 社團法人台灣生物產業發展協會 Taiwan Bio Industry Organization, All rights reserved. Room229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia
The Jobs Fund HOME THE JOBS FUND About the Jobs Fund Governance & management CHALLENGE FUND MODEL TYPES OF FUNDING Enterprise development Infrastructure Support for work seekers Institutional capacity building APPLY TO THE FUND Current call for proposals Application stages & process FUNDED PROJECTS Enterprise development Infrastructure Institutional capacity building Support for work seekers PYEI NEWS PUBLICATIONS GALLERY OUR STORIES FAQS CONTACT US Pharmacy Assistant Training Initiative Project Partner name: Medipost Pharmacy Project name: Pharmacy Assistant Training Initiative Funding … name: Pharmacy Assistant Training Initiative Funding round: CFP 1 Funding: Jobs Fund grant R6 572 000 Matched Funding R6 572 000 Website: http://www.medipost.co.za Window: Work seekers Location: National Partners: None Problem statement: The pharmaceutical sector has a shortage of pharmacy assistants and point-of-sale assistants. Partner(s): In 1991, Medipost Pharmacy, South Africa’s first national pharmacy, started to regularly deliver medication to its customers. Interventi
MEDIPOST Careers | Levels.fyi Download App Change Login Sign Up All Data By Location By Company By Title Salary Calculator Chart Visualizations Verified Salaries Internships H-1B Salaries Negotiation Support Compare Benefits Who's Hiring 2025 Pay Report Top Paying Companies Integrate Blog Press Google Software Engineer Product Manager New York City Area Data Scientist Explore By Different Titles Levels FYI Logo Salaries 📂 All Data 🌎 By Location 🏢 By Company 🖋 By Title 🏭️ By Industry 📍 Salary Heatmap 📈 Chart Visualizations 🔥 Real-time Percentiles 🎓 Internships 🛂 H-1B Salaries ❣️ … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Featured Jobs No featured jobs found for MEDIPOST Related Companies Landmark Bio BostonGene Integrium Clinical Research Boston Heart Diagnostics CTMC See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Featured Jobs No featured jobs found for MEDIPOST Related Companies Landmark Bio BostonGene Integrium Clinical Research Boston Heart Diagnostics CTMC See all compa
Home - Medipost Pharmacy Pay Account Track my Parcel Careers Online Shop 012 426 4000 [email protected] 012 426 4655 Home About Us Why Us? Company Structure Socio Economic Development Oncology Service Provider Application Collection Points Info Patient Info Form Payment Methods Careers Links FAQ Online Shop POPIA Privacy Statement PAIA Manual PAIA Manual – Zulu PAIA – How To Guide Legal Documents Contacts Contact Us Update Your Details Confidential HIV Enquiries Compliments Complaints Send My Medication Speak Confidentially To A Pharmacist News Hub Speak Confidentially To A Pharmacist … l and efficient service Contracted to most Medical Schemes Assists with chronic application process Reduced dispensing fees New prescription reminders Various support mechanisms in place to ensure compliance Comprehensive and customized reporting capabilities Co-payments can be made by debit order, credit card or direct deposit About Us In 1991 Medipost Pharmacy identified a need amongst its customers to have their medication delivered to them on a regular basis. Market resea
MEDIPOST | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas MEDIPOST Website: MEDIPOST Business Area(s) Stem Cells Description Stem cell technology & regenerative medicine Company Location(s) Seoul South Korea body Sign up for news Contact Us Add an Employer About the Site Site's Purpose and Use Articles People in Biotech Biotech Careers Biotechnology
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Medipost Holdings | Home Skip to main content Home Jobs Recruiters Employees Login / Upload CV For employees For recruiters Login / register × We are hiring... Start your journey with US Register your CV Looking for a new challenge? Join our team LATEST VACANCIES If you're ready for a new and challenging job, take a look at our latest vacancies, register your CV and apply. DISPENSARY CAREERS We're looking for permanent and locum Pharmacy Professionals to join our company. If you are a qualified Pharmacist or Pharmacist Assistant please click here for an HR Consultant to contact you directly. R
MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochu
Medipost Holdings | Job search Skip to main content Home Jobs Recruiters Employees Login / Upload CV For employees For recruiters Login / register × Our available positions Positions: External applyform internalapplyform minimumexperience name reference reportingto Search Searching for Clear All Category Location 10 25 50 100 Privacy Statement Disclaimer Terms & Conditions × Applicant Login Sign Up Username Password Forgot password? Login By clicking on the above you are agreeing to this site's Terms of Use . Read our full Data Protection Policy here . I'm a recruiter Information: *
MEDIPOST will set up a joint venture company in China – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D I
Medipost Cartistem Completion of Phase 3 clinical trials in Japan, etc. Industry Finance Stock Deep analysis Issue tracking Governance Interview Medipost Cartistem Completion of Phase 3 clinical trials in Japan, etc. Industry Finance Stock Deep analysis Issue tracking Governance Interview KOREAN TOP's Pick Pharm&Bio Medipost Cartistem Completion of Phase 3 clinical trials in Japan, etc. By Hongki Choi , Koo Yerim March 3, 2026 at 4:26pm Share facebook x linkedin url print Resize A small A medium A large International Pharmaceuticals Glaucoma Improved New Drug 'TFC003' Progresses Smooth … of this year and release the results in the second quarter. The company aims to apply for product approval in the second half of the year, with the goal of obtaining Japanese approval by the end of 2027. One-line comment => Announcement of results for the second quarter of this year with acquisition of all patient data. Kukje Pharmaceutical's new glaucoma drug, TFC003, is progressing smoothly through clinical trials and approval. Photo = International Pharmaceutical Kukje P … g its development schedule, aiming to issue a clinical trial report in 2027 and apply for product approval from the Ministry of Food and Drug Safety (MFDS), with formal approval and product launch in 2028. TFC003 is an improved drug that can shorten the development period compared to existing treatments, allowing for a relatively rapid market entry. The clinical trial will evaluate a multi-drug combination eye drop for patients with glaucoma and elevated intraocular pressure … newly selected this year, until graduation. The foundation will also operate a scholarship program worth approximately 3 billion won annually across public interest projects, including academic programs. Of the selected students, 168 will receive a total of 1.1 billion won in tuition and living expenses. The 98 scholarship recipients (57 domestic, 41 international) will receive full tuition, while the 70 scholarship recipients will receive a monthly stipend of 500,000 won. 2
STEM CELL THERAPEUTIC – Page 10 – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO In
MEDIPOST Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 29 Jan 2026 MEDIPOST Co., Ltd. Public Company | 2000 | Gyeonggi-do, South Korea | 250-500 | KRX: 078160 | www.medi-post.co.kr Public Company | 2000 | Gyeonggi-do, South Korea | 250-500 | KRX: 078160 | www.medi-post.co.kr Last update 29 Jan 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Mesenchymal stem cell therapy … rescendo Equity Partners, with participation from Korea's leading growth equity fund.MEDIPOST's Cartistem — which comprises allogeneic umbilical cord blood-derived MSCs — has been approved in the company's domestic market since 2012. In the US, the firm has finished Phase I/IIa testing and plans to start a late-stage study early this year.The new funds will be used to expand scientific and operational capabilities, build infrastructure and scale manufacturing processes.a16z's … + Health unit teamed up with Eli Lilly to launch the Biotech Ecosystem Venture Fund with $500 million to tackle healthcare's "complex challenges." In 2025, a16z backed biotech firms including Cartography Biosciences and Gate Bioscience, and began 2026 by investing in AI-powered drug development startup Boltz Lab. The financing — which, across all of a16z's funds, reached $15 billion — is intended to help the US retain its top spot as the global technology leader in a landsca … rescendo Equity Partners, with participation from Korea’s leading growth equity fund, was completed at the parent-company level and will accelerate the company’s Phase III trial of its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in patients with knee osteoarthritis, an inflammation-driven degenerative disease, by expanding scientific and operational capabilities, building infrastructure, and scaling manufacturing processes. “The … act. Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing , Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and n
MEDIPOST Secures FDA Agreement for CARTISTEM in Knee Osteoarthritis | Jack Shuang Hou posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … cell therapy #CARTISTEM ®, securing FDA agreement to pursue a Biologics License Application (BLA) based on a single pivotal U.S. Phase 3 study supported by international Phase 3 data and real-world evidence. The decision could significantly accelerate U.S. commercialization of one of the most established allogeneic cell therapies globally. 1️⃣ FDA Supports Streamlined U.S. Development Strategy The FDA agreed that MEDIPOST, Inc. can pursue approval using: 📌 One pivotal U.S. P
MEDIPOST America Clears Phase 1/2 IND For The U.S. Clinical Trial On Stem Cell Drug For Lung - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development MEDIPOST America Clears Phase 1/2 IND For The U.S. Clinical Trial On Stem Cell Drug For Lung September 15, 2014 | 1 min read Twitter LinkedIn Facebook Email Print ROCKVILLE, Md.--(BUSINESS WIRE)--MEDIPOST America Inc. (CEO: Dr. Antonio Lee) today announced the US FDA approval of Phase … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankruptcy Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy June 23, 2026 · 3 min read · Gabrie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S. June 4, 2026 | 2 min read Twitter LinkedIn Facebook Email Print SEOUL, South Korea , June 3, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell ther … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Inflammatory bowel disease Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms June 23, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MEDIPOST, Inc. Expands U.S. Presence with Key Executive Appointments, advances toward Phase III clinical trial of CARTISTEM® in North America - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufac … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MEDIPOST, Inc. Expands U.S. Presence with Key Executive Appointments, advances toward Phase III clinical trial of CARTISTEM® in North America December 3, 2024 | 3 min read Twitter LinkedIn Facebook Email Print CAMBRIDGE, Mass.--(BUSINESS WIRE)-- MEDIPOST, Inc. , a global leader in stem cell-based therapeu … to initiate a Phase III clinical trial, paving the way for a Biologics License Application (BLA) and a successful commercial launch in North America. The new executive appointments follow MEDIPOST’s recent manufacturing partnership with OmniaBio and the opening of OmniaBio’s state-of-the-art cell and gene therapy manufacturing facility in Ontario. MEDIPOST’s collaboration with OmniaBio positions the company to leverage over a decade of expertise in cell and gene therapy manu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial February 13, 2026 | 1 min read Twitter LinkedIn Facebook Email Print Submission marks key step in study of mesenchymal stem cell therapy to treat symptomatic cartilage defects in patients with knee osteo … sp; 3 min read · Heather McKenzie Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Inflammatory bowel disease Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms June 23, 2026 · 2 min read · Tristan Manalac Lung cancer Pfizer delivers ‘disappointing’ late-stage lung cancer data … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Stem Cell Therapy Market Growing at 18.2% CAGR During (2022-2028) to Reach USD 6.2 Billion | The Insight Partners - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Stem Cell Therapy Market Growing at 18.2% CAGR During (2022-2028) to Reach USD 6.2 Billion | The Insight Partners April 25, 2023 | 6 min read Twitter LinkedIn Facebook Email Print The Insight Partners published latest research report on “Stem Cell Therapy Market Size Report, Revenue, Trends, Segments, Share & Foreca … mp; Forecasts to 2028 - COVID-19 Impact and Global Analysis By Type, Treatment, Application, End User and Geography”, The Insight Partners published latest research report on " Stem Cell Therapy Market Size Report, Revenue, Trends, Segments, Share & Forecasts to 2028 - COVID-19 Impact and Global Analysis By Type, Treatment, Application, End User and Geography”, the global market is expected to grow from USD 2,278.49 million in 2022 to USD 6,206.89 million by 2028; it is e … he COVID-19 pandemic had a positive impact on the stem cell therapy market. The application of stem cells in the treatment of COVID-19 infection has gathered the attention of medical researchers, resulting in a higher number of clinical trials. Regenerative medicine based on cellular therapies may be developed as a treatment option for patients, lowering infection rates and mortality. Research institutes and companies are collaborating to develop novel treatment options for C … nstitute and Celularity announced that the US FDA had approved a clinical trial application to develop cell-based therapy for COVID-19. Thus, researchers are increasingly attempting to develop stem cell therapies targeting COVID-19. In January 2020, researchers from the University of Miami administered two stem cell infusions to COVID-19 patients
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search New … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control May 14, 2026 | 4 min read Twitter LinkedIn Facebook Email Print - Achieved statistical significance versus standard-of-care (SOC) control a … rengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026 SEOUL, South Korea and TOKYO , May 14, 2026 /PRNewswire/ -- MEDIPOST has met all primary and secondary efficacy endpoints in the Japan Phase 3 clinical trial of CARTISTEM ® , demonstrating clinical improvements in pain and function as well as cartilage regeneration. Based on the results, MEDIPOST is expected to accelerate preparations for its biologics licen … ults, MEDIPOST is expected to accelerate preparations for its biologics license application (BLA) filing in Japan later this year. MEDIPOST (CEO Wonil Oh), a global leader in stem cell biotherapeutics, announced today that the Japan Phase 3 clinical trial of its knee osteoarthritis treatment CARTISTEM ® achieved statistical significance across all primary and secondary efficacy endpoints. The results showed improvements not only in symptoms, including pain and function, but a … rate its entry into the Japanese market by submitting a marketing authorization application later this year, targeting regulatory approval by end of 2027. The company has already established a commercial partnership through an exclusive distribution agreement with Teikoku Seiyaku Co., Ltd.. Following regulatory approval and commercial launch, MED
Publications – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO Inquiries IR Inquiries Inst
Government engagement bodes well for life sciences | Insights | Torys LLP You need to enable JavaScript to run this app. Skip to main content Our People Our Services Our Latest Thinking About Us Careers Offices Menu Q4 | Torys Quarterly • Fall 2022 Government engagement bodes well for life sciences Open Article Navigation Q4 Torys Quarterly: Canadian sector report Subscribe As public markets enter bear territory and the IPO window remains shut for the time being, the impact is being felt on deal flow in the Canadian life sciences sector. Yet the outlook remains strong for the sector, in part b … e investments in local life sciences companies through its Strategic Innovation Fund, such as its $175.6 million investment in AbCellera Biologics. It has committed $92 million to adMare BioInnovations, a not-for-profit organization that supports companies in the Canadian life sciences industry with expertise, infrastructure and capital. Additional support is also being provided for the conduct of clinical trials in Canada, with $250 million being allocated to a clinical tria … inical trials in Canada, with $250 million being allocated to a clinical trials fund to be administered by the Canadian Institutes of Health Research. Canadian venture capital funds are also receiving a boost, with a new $450 million Venture Capital Catalyst Initiative announced last year—$50 million of which is specifically allocated to life sciences. With the deadline for life sciences applications now expired, the program continues to progress, and these funds are cl … male entrepreneurs and investors across the country, through its Thrive Venture Fund and Lab for Women. Provincial governments adding their own value Provincial governments across the country have taken their cue from Ottawa and launched their own significant initiatives tailored to their local life sciences ecosystem. Like the federal government, they have focused on financing and partnering with life sciences companies and by working with not-for-profit organizations that s
MEDIPOST, Inc. Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Therapies MEDIPOST specializes in umbilical cord-derived stem cell therapies, with its flagship product CARTISTEM being a pioneering allogeneic stem cell treatment for joint cartilage repair, presenting opportunities for partnerships or supply agreements in regenerative medicine markets. Strategic Partnerships The company's recent licensing agreement with Teikoku Seiyaku to commercialize C
Instagram Instagram Log In Sign Up Close Never miss a post from ccrm_ca Sign up for Instagram to stay in the loop. Sign up Log in ccrm_ca • Follow More options ccrm_ca 87w Today, OmniaBio Inc. will announce the opening of a new North American cell and gene therapy ( #CGT ) manufacturing and artificial intelligence ( #AI ) centre of excellence, which is now Canada’s largest contract development and manufacturing organization ( #CDMO ) facility dedicated to CGT. Based in Hamilton, Ontario, the facility is a groundbreaking development for both the Canadian biotech industry and the broader global
Medipost CEO on why Massachusetts is a biotech hub | MEDIPOST Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
MEDIPOST Secures $140M for Allogeneic Stem Cell Therapy | Jesse Landry posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
MOVITA Nutritional Supplements – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO Inquiries
MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development January 9, 2026 | 2 min read Twitter LinkedIn Facebook Email Print Funding will support a planned Phase III U.S. clinical trial in 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company de … rescendo Equity Partners, with participation from Korea’s leading growth equity fund, was completed at the parent-company level and will accelerate the company’s Phase III trial of its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in patients with knee osteoarthritis, an inflammation-driven degenerative disease, by expanding scientific and operational capabilities, building infrastructure, and scaling manufacturing processes. “The … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Medipost CEO on Citeline's In Vivo Podcast | MEDIPOST Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Lin … Editor: Dr. Moo Kon Song 🔗 Find Out More: https://lnkd.in/eyb8V-3P ⏰Submission Deadline: 𝟐𝟎 𝐅𝐞𝐛𝐫𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟔 #AcuteMyeloidLeukemia #AML #Leukemia #CancerTreatment #CallforPapers #OpenAccess #MDPIIJMS #HaeundaeBuminHospital Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 2,201 followers View Profile Connect Explore related topics Stem Cell Therapy Developments Stem Cell Uses in Cardiology Innovations Driving Scalability in Cell Therapy
Stream “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision by Citeline | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision by Citeline published on 2025-07-16T15:33:51Z The latest episode of the In Vivo podcast features an interview Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel
Episode 185 - Ed Ahn - Medipos... - The BioHub - by Avetix - Apple Podcasts بحث الرئيسية جديد قوائم الأفضل بحث ٥ يونيو ٢٥ د Episode 185 - Ed Ahn - Medipost INC The BioHub - by Avetix تشغيل Today's guest is Edward Ahn, CEO of MEDIPOST Inc., a biotechnology company at the forefront of regenerative medicine and stem cell therapeutics. Based in Cambridge, Massachusetts, MEDIPOST is leading the global development of innovative cell therapies designed to address inflammation-driven degenerative diseases, with a mission to move beyond symptom management and toward true disease modification. Edward le
Empowered Patient Podcast: Next-Generation Stem Cell Therapy for Inflammation-Driven Degenerative Diseases with Ed Ahn MEDIPOST Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Protesting Healthcare workers Hospita … ing experience and know-how from our parent company in Korea that we're able to apply to our manufacturing process in North America. And that really advances and matures our program far beyond other people in the field." #MEDIPOST #CARTISTEM #StemCellTherapy #KneeOsteoarthritis #RegenerativeMedicine #Innovation #Healthcare #Biotech #ClinicalTrials #JointHealth #AntiAging #MedicalBreakthrough #BiotechInnovation medipost.com Download the transcript here × Abo … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
Episode 185 - Ed Ahn - Medipost INC - The BioHub - by Avetix | Podcast on Spotify
Agilent–JPMorgan Chase: investor conference, 202601 supply service Agilent presents at JP Morgan Healthcare Conference 2026 - [MSC] Mass-Spec-Capital.com - The Mass Spectrometry Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck Appoints Two Life Sciences Leadership Team Members Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Charles River Labs and Medipost Sign Non-Exclusive MOU Brainomix and Boehringer Expand Strategic Partnership in PPF Agilent at Jefferies Global Healthcare Conference 2026 Agilent Names Michael Buckner as Ch … t Partners with OmixAI (KR) for AI-Driven Proteomics » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) DxPx U.S. Conference 2026 Anaheim ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim Canaccord Genu … 26 Cologne (Köln) PEGS Europe 2026 Lisboa (Lisbon) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Camila Japur Joins Tecan as CFO on 1 Jun 2026 Birgit Girshick Succeeds Jim Foster as CEO of Charles River Agilent Names Michael Buckner as Chief Legal Officer Kai Beckmann to Succeed Belén Garijo as CEO of Merck KGaA Bruker Appoints Qiagen CE … cks Appoints Darren Sher as Chief Commercial Officer » More News! » Submit your News! Financings & Acquisitions Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Alamar Biosciences Closes Upsized $219.9m IPO at Nasdaq Proteins.1 Raises €4.7m in Pre-Seed Funding to Pioneer Omics Shimadzu Acquires 75% Majority in Plasmion GmbH Agilent to Acquire Biocare Medical for $950m in Cash Danaher to Acquire Masimo for $9.9b Total Enterprise Value CubaseBio Receives … naher to Acquire Masimo for $9.9b Total Enterprise Value CubaseBio Receives €2m Grant from EI Transition Programme bioMérieux Acquires Remaining 90% of Accellix for €35m Cash Charles River to Acquire Paris-based PathoQuest Bruker Acquires Remaining 60% Ownership in TOFwerk AG » More News! » Submit your News! Collaborations & Licensing
GMP Center – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO Inquiries IR Inquiries Instit
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Convince your boss - Plastics Live 2027 - Plastics Live 2024 Plastics Live 2027 | Coventry Building Society Arena, Coventry, UK | June 2027 Colocated with: Exhibit at Plastics Live 2025 Register to visit Plastics Live 2027 | Coventry Building Society Arena, Coventry, UK | June 2027 Colocated with: Visit Plastics Live Exhibit Why exhibit? Book your stand Exhibiting details Why should you be exhibiting? Top Tips for Exhibitors Common Exhibitor Mistakes Attract and Quality Quality Leads Plastics Live Conference 2024 Sustainable Plastics Live Conference UKCPN Conference Speakers Book Your Hotel Es … eption would be like. We were also soft-launching and revealing our drug safety application for the first time - so it was a nervous few weeks leading up to the expo. All the anxiety was misplaced though, as the team were absolutely professional and on the ball with everything! There was no question too silly or obvious, and they walked me through the process with utter calm. The expo itself was a source of great positive feedback from the visitors, and the exposure it gave u
The only Korean company invited to North American Rare Medicine conference – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Custo
Instagram Instagram Log In Sign Up Close Never miss a post from ccrm_ca Sign up for Instagram to stay in the loop. Sign up Log in ccrm_ca • Follow More options ccrm_ca 87w Today, OmniaBio Inc. will announce the opening of a new North American cell and gene therapy ( #CGT ) manufacturing and artificial intelligence ( #AI ) centre of excellence, which is now Canada’s largest contract development and manufacturing organization ( #CDMO ) facility dedicated to CGT. Based in Hamilton, Ontario, the facility is a groundbreaking development for both the Canadian biotech industry and the broader global
Exhibitor List Go Back Exhibitor List ABOK Pharmaceuticals Pty (LTD) Stand: B8 - Expo Hall 1 Exhibitor ACS Pharma Stand: A8 - Expo Hall 1 Exhibitor Adcock Ingram GIT-BIO-VAC Stand: B19 - Expo Hall 1 Exhibitor Adcock Ingram Vaccines Stand: B19a - Expo Hall 1 Exhibitor AfricaBUD Stand: G01 - Expo Hall 2 Exhibitor Afridose Stand: I2 - Expo Hall 2 Exhibitor AGRI-ENVIRO SOLUTIONS Stand: H22 - Expo Hall 2 Exhibitor AGRISMART ENGINEERING Stand: E01 - Expo Hall 2 Exhibitor Air Charter Service Pty Ltd Stand: H19 - Expo Hall 2 Exhibitor ALPHA INSURE Stand: C23 - Expo Hall 1 Exhibitor Ambasaam Stand: B12
2025 Sponsors & Exhibitors – OSET | Orthopaedic Summit Login Login Forgot Password Register Fontainebleau Hotel | Las Vegas December 2 – December 5, 2026 Home About Why Attend FAQs Contact Program Program Overview Knee & Hip Arthroplasty Knee Sports Shoulder Sports & Arthroplasty Trauma Nonoperative MSK & Sports Optimization Advanced Practice Practitioner Orthopaedic Sports Rehab Hip Sports Fellow, Resident & Medical Student Research Summit Spotlight Sessions Theatre in the Round Faculty Abstract Travel Exhibit Exhibitor Information 2026 Digital Prospectus 2025 S
𝗦𝗔𝗣𝗛𝗘𝗫 𝟮𝟬𝟮𝟲 𝘊𝘰-𝘭𝘰𝘤𝘢𝘵𝘦𝘥 𝘸𝘪𝘵𝘩:... - Sandton Convention Centre Facebook Log In Sandton Convention Centre's Post Sandton Convention Centre Verified account January 29 · Shared with Public 𝗦𝗔𝗣𝗛𝗘𝗫 𝟮𝟬𝟮𝟲 𝘊𝘰-𝘭𝘰𝘤𝘢𝘵𝘦𝘥 𝘸𝘪𝘵𝘩: 𝘛𝘩𝘦 𝘗𝘩𝘢𝘳𝘮𝘢𝘤𝘺 𝘚𝘩𝘰𝘸, 𝘎𝘗 𝘌𝘹𝘱𝘰, 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘚𝘩𝘰𝘸, 𝘋𝘪𝘨𝘪𝘵𝘢𝘭 𝘏𝘦𝘢𝘭𝘵𝘩 𝘚𝘩𝘰𝘸, 𝘔𝘊𝘉𝘊 𝗦𝗔𝗣𝗛𝗘𝗫 𝟮𝟬𝟮𝟲 is Africa’s leading pharmaceutical and healthcare exhibition, co-located with The Pharmacy Show, GP Expo, Hospital Show, Digital Health Show, and MCBC. Taking place at the 𝗦𝗮𝗻𝗱𝘁𝗼𝗻 𝗖𝗼
MEDIPOST to showcase the competitive edge of its stem cell therapy ‘Cartistem’ at BIO KOREA 주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기 잠깐! 현재 Internet Explorer 8이하 버전을 이용중이십니다. 최신 브라우저(Browser) 사용을 권장드립니다! ie 인터넷 익스플로러 11 다운로드 chrome 구글 크롬 다운로드 firefox 모질라 파이어폭스 다운로드 --> 편집 : 2026-06-25 12:03 (목) 제보 이슈모아보기 로그인 유료회원가입 검색버튼 상세검색 기사검색 검색 전체메뉴 버튼 전체기사 ENGLISH NEWS The interview 암 희귀질환 주요질환 헬스케어·AI 기술이전·투자·IPO THE FINANCE 학회줌인 VC insight PREMIUM 이전 기사보기 다음 기사보기 MEDIPOST to showcase the competitive edge of its stem cell therapy ‘Cartistem’ at BIO KOREA 스크롤 이동 상태바 홈 ENGLISH NEWS 기업·일반 … dicine (CARM), Regenerative Medicine Acceleration Foundation (RMAF), and Korean Fund for Regenerative Medicine (KFRM), under the auspices of the Ministry of Health and Welfare. Through its participation, MEDIPOST plans to actively promote its advanced regenerative medicine capabilities and key products to both domestic and international markets, while expanding engagement with global biohealth companies and experts. In addition, the company intends to strengthen direct commun … In February, MEDIPOST received approval for its Investigational New Drug (IND) application to initiate Phase 3 clinical trials in the United States for its knee osteoarthritis stem cell therapy, ‘CARTISTEM.’ The company is currently accelerating clinical development with the objective of enrolling its first patient (First Patient In, FPI) in the first half of the year. MEDIPOST further plans to pursue U.S. marketing approval by around 2031, followed by a commerci
Medipost Pharmacy - FPS Events - Exhibitor Directory Home Upcoming Events SAPHEX & Co-Located Events 2027 Past Events SOUTH AFRICA SAPHEX & Co-Located Events 2026 Search our events Generic selectors Exact matches only Search in title Search in content Post Type Selectors Home Upcoming Events SAPHEX & Co-Located Events 2027 Past Events SOUTH AFRICA SAPHEX & Co-Located Events 2026 Generic selectors Exact matches only Search in title Search in content Post Type Selectors SAPHEX & Co-Located Events 25th-26th March 2026 Sandton Convention Centre, Johannesburg Book a stand today Regi
MEDIPOST presents the development progress of its next-generation injectable drug for knee osteoarthritis in the Spring Conference of the Korean Orthopedic Surgeons Association – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026 | PharmExec --> --> News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Shorts Conferences Conference Coverage Conference Listing More Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe My Account News Academy Multimedia Conferences Publications Partner Perspectives Resources Subscribe Corporate Communications Press Releases Executive Roundtable Executive Profiles Lea
Clinical Trials of Expanded Cord Blood Skip to main content ® Toggle navigation About Cord Blood Birth in My Country Cord Blood Value How Banks Work Infographic FAQs Family Banking Family Banks in My Country World Map Family Banks Help for families in need Public Donation The Youngest Donor How to Donate Cord Blood USA Donation Hospitals Public Banks in My Country World Map Public Banks Therapies Available Diseases Treated Clinical Trials Cord Blood Clinical Trials Cord Tissue Odds of use Milestones Cord Blood Resources Parent Brochures Delayed Cord Clamping Accreditation Standar … aematopoietic stem cells Rezvani K., Rouce RH. Front. Immunol. 2015; 6:578. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Thompson PA. et al. Bone Marrow Trans. 2015; 50:S55–S62 Umbilical cord blood graft engineering: challenges and opportunities Schmeel LC. et al. J Cancer Res Clin Oncol. 2015; 141(5):839-49. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC) Dave H. et al.
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance More News Today's news Singapore Politics Southeast Asia World Sports Personal Finance Property Weather Lifestyle Travel Health Fashion Celebrity Parenting Food Finance My portfolio Markets Watchlists Screeners Money News Cryptocurrencies Industries Property Sign in My Portfolio News Stocks Singapore Economics Property Tec … rengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026 SEOUL, South Korea and TOKYO, May 14, 2026 /PRNewswire/ -- MEDIPOST has met all primary and secondary efficacy endpoints in the Japan Phase 3 clinical trial of CARTISTEM®, demonstrating clinical improvements in pain and function as well as cartilage regeneration. Based on the results, MEDIPOST is expected to accelerate preparations for its biologics license … ults, MEDIPOST is expected to accelerate preparations for its biologics license application (BLA) filing in Japan later this year. MEDIPOST CARTISTEM® Japan Phase 3 Results Press Conference – Antonio Lee, Executive Vice President of Global Business Division at MEDIPOST MEDIPOST (CEO Wonil Oh), a global leader in stem cell biotherapeutics, announced today that the Japan Phase 3 clinical trial of its knee osteoarthritis treatment CARTISTEM® achieved statistical significance acr … rate its entry into the Japanese market by submitting a marketing authorization application later this year, targeting regulatory approval by end of 2027. The company has already established a commercial partnership through an exclusive distribution agreement with Teikoku Seiyaku Co., Ltd.. Following regulatory approval and commercial launch, MEDIPOST expects to generate tangible business outcomes in Japan through finished product supply revenues and sales-based milestone pay
MEDIPOST Leverages Agreement for US Phase 3 Study | BioPharma APAC posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … this post Yesterday Teva Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. FDA for a first-in-class investigational therapy for pediatric Tourette syndrome - a condition where new treatment options could make a meaningful difference for patients and families. This milestone reflects the power of focused strategy in action: identifying areas where we can make a meaningful impact, investing in promising science, and executing with discipline t … or Teva Pharmaceuticals and patients. We announced the submission of a New Drug Application (NDA) to the US FDA for a first-in-class investigational therapy for pediatric Tourette syndrome - a condition where additional treatment options are needed. This is what focused innovation looks like. Promising science. Disciplined execution. A pipeline focused on areas where Teva is working to address significant unmet need. It is also a reminder of why strategic partnerships matter.
AACR Annual Meeting 2020 San Diego American Association for Cancer Research (AACR) - [MSC] Mass-Spec-Capital.com - The Mass Spectrometry Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck Appoints Two Life Sciences Leadership Team Members Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Charles River Labs and Medipost Sign Non-Exclusive MOU Brainomix and Boehringer Expand Strategic Partnership in PPF Agilent at Jefferies Global Healthcare Conference 2026 Agilent Names Michael Buckner as Chief Legal Officer Shimadzu Acquires 75% M … t Partners with OmixAI (KR) for AI-Driven Proteomics » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) DxPx U.S. Conference 2026 Anaheim ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim Canaccord Genu … 26 Cologne (Köln) PEGS Europe 2026 Lisboa (Lisbon) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Camila Japur Joins Tecan as CFO on 1 Jun 2026 Birgit Girshick Succeeds Jim Foster as CEO of Charles River Agilent Names Michael Buckner as Chief Legal Officer Kai Beckmann to Succeed Belén Garijo as CEO of Merck KGaA Bruker Appoints Qiagen CE … cks Appoints Darren Sher as Chief Commercial Officer » More News! » Submit your News! Financings & Acquisitions Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Alamar Biosciences Closes Upsized $219.9m IPO at Nasdaq Proteins.1 Raises €4.7m in Pre-Seed Funding to Pioneer Omics Shimadzu Acquires 75% Majority in Plasmion GmbH Agilent to Acquire Biocare Medical for $950m in Cash Danaher to Acquire Masimo for $9.9b Total Enterprise Value CubaseBio Receives … naher to Acquire Masimo for $9.9b Total Enterprise Value CubaseBio Receives €2m Grant from EI Transition Programme bioMérieux Acquires Remaining 90% of Accellix for €35m Cash Charles River to Acquire Paris-based PathoQuest Bruker Acquires Remaining 60% Ownership in TOFwerk AG » More News! » Submit your News! Collaborations & Licensing
Number of patients getting Cartistem tops 30,000: Medipost 주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기 잠깐! 현재 Internet Explorer 8이하 버전을 이용중이십니다. 최신 브라우저(Browser) 사용을 권장드립니다! ie 인터넷 익스플로러 11 다운로드 chrome 구글 크롬 다운로드 firefox 모질라 파이어폭스 다운로드 상단영역 UPDATE : 2026-06-25 12:01 (Thurs) Home Log in Join 전체메뉴 기사검색 검색 본문영역 이전 기사보기 다음 기사보기 Number of patients getting Cartistem tops 30,000: Medipost 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 스크롤 이동 상태바 현재위치 Home Bio Number of patients getting Cartistem tops 30,000: Medipost 기자명 Kim Chan-hyuk Published 2024.06.24 14:22 Comments 0 --> 바로가기 복사하기 본문 글씨 줄이기 … l, the company focuses on preparing for the Investigational New Drug (IND) application for a phase 3 clinical trial, skipping phase 2, and finalizing the clinical protocol through a meeting with the U.S. FDA. The Japanese trial has entered phase 3, skipping phases 1 and 2, with more than 90 percent of the targeted patients enrolled and screening and dosing underway, with patient dosing targeted for the second half of this year. Medipost attended the 2024 Bio Internationa … nadian affiliate opens cell and gene CDMO facility Regulator rejects Medipost's application to expand Cartistem's indication for ankle joint treatment Expert tips to prevent knee osteoarthritis: diet, exercise, and lifestyle ‘Cartistem proves regenerative effect regardless of meniscus condition’ MEDIPOST’s stem cell therapy regenerates stronger cartilage than microdrilling, clears path to US phase 3 MEDIPOST snags ₩205 bil. to fund US phase 3 for CARTISTEM knee osteoarthritis … forming Biosplice drug in animal tests Comments Log In 작성자 비밀번호 댓글 내용입력 0 / 400 Submit 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More Delete comments Deleted comments cannot be recovered. Do you still want to delete it? Password Delete 닫기 Modify the comments You can modify comments only within 1 minute after writing. Text / 400 Password Modify 닫기 My comme
MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 Patients – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Cen … finalizing clinical protocols and preparing the Investigational New Drug (IND) application for Phase 3 clinical trials. In Japan, CARTISTEM ® has also bypassed Phases 1 and 2, advancing directly to Phase 3, where more than 90% of the target patient enrollment has been completed. Screening and administration are currently underway, with full administration expected to conclude in the second half of this year. To drive its global expansion, MEDIPOST participated in the 2024 BI
MEDIPOST, announces the clinical trial achievements at Bio USA – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R
BIO 2027 Philadelphia (BIO International Convention) BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) - [MSC] Mass-Spec-Capital.com - The Mass Spectrometry Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck Appoints Two Life Sciences Leadership Team Members Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Charles River Labs and Medipost Sign Non-Exclusive MOU Brainomix and Boehringer Expand Strategic Partnership in PPF Agilent at Jefferies Global Healthcare Conference 2026 Agilent Nam … t Partners with OmixAI (KR) for AI-Driven Proteomics » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) DxPx U.S. Conference 2026 Anaheim ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim Canaccord Genu … 26 Cologne (Köln) PEGS Europe 2026 Lisboa (Lisbon) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Camila Japur Joins Tecan as CFO on 1 Jun 2026 Birgit Girshick Succeeds Jim Foster as CEO of Charles River Agilent Names Michael Buckner as Chief Legal Officer Kai Beckmann to Succeed Belén Garijo as CEO of Merck KGaA Bruker Appoints Qiagen CE … cks Appoints Darren Sher as Chief Commercial Officer » More News! » Submit your News! Financings & Acquisitions Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Alamar Biosciences Closes Upsized $219.9m IPO at Nasdaq Proteins.1 Raises €4.7m in Pre-Seed Funding to Pioneer Omics Shimadzu Acquires 75% Majority in Plasmion GmbH Agilent to Acquire Biocare Medical for $950m in Cash Danaher to Acquire Masimo for $9.9b Total Enterprise Value CubaseBio Receives … naher to Acquire Masimo for $9.9b Total Enterprise Value CubaseBio Receives €2m Grant from EI Transition Programme bioMérieux Acquires Remaining 90% of Accellix for €35m Cash Charles River to Acquire Paris-based PathoQuest Bruker Acquires Remaining 60% Ownership in TOFwerk AG » More News! » Submit your News! Collaborations & Licensing
A Biotech Business Model To Convince Investors Get more pharma outsourcing insight with our FREE newsletter sign me up Log In or Subscribe Explore CDMO Outsourcing Outsourcing 101 Preparing to Outsource Selecting a CDMO Onboarding & Tech Transfer Managing CDMOs Find Suppliers Bioanalytical Services Biologic Drug Substance Biologic Drug Product Cell & Gene Clinical Supply Fill/Finish Small Molecule API Small Molecule Drug Product Watch Now STREAM Video Channel Outsourced Pharma Capabilities Update Outsourced Pharma Live The Outsourcing Advisor Events CDMO Leadership Awards CDMO Live Ame … number of things last year,” he says. “‘We will raise money; submit an IND amendment; complete our Japanese Phase III trial, and we will execute a Japanese commercial partnership.’” There was a lot of questioning: ‘That's a long list of big stuff. Are you guys really going to be able to do all of that?’ is what Ahn heard. He returned to inform investors that MEDIPOST had indeed raised $140 million; submitted an IND amendment and
Medical supplier's first anniversary | Dorset Echo Public notices Newsletters Jobs Book an ad Cars Homes Local listings Local info More Public notices Newsletters Jobs Book an ad Cars Homes Local listings Local info Subscribe Digital Edition Puzzles Close Stay ahead with a digital subscription Subscribe Search News Districts Features In The Dock Public Notices Picture Galleries UK News Crime Sport Local Sport Afloat Football Terras Magpies Cricket Basketball Rugby Photo Galleries Your Say Your Letters Submit a letter What's On Local Events Showbiz Notices Bereavement Guide Newspaper Archive Su … d & Wales | 01676637 Modal headline Close Automatically injected HTML goes here Submit Cancel Deactivate Piano meter debugger Data returned from the Piano 'meterActive/meterExpired' callback event . --> As a subscriber, you are shown 80% less display advertising when reading our articles. Those ads you do see are predominantly from local businesses promoting local services . These adverts enable local businesses to get in front of their target audience – the local community .
MEDIPOST joins BIO Asia-Taiwan conference while advancing into Asian market - CHOSUNBIZ
Page 8 – Korean-American Professional Association in Life Sciences ::: 한미 생명과학인 협회 Skip to content Search for: Menu Home About Us Post Event Networking Career Photo Gallery Sponsors Information Announcement News Job posting Contact Us The 9th KAPAL Annual Conference Program KAC Information Sponsors & Participants Korean-American Professional Association in Life Sciences ::: 한미 생명과학인 협회 March 31, 2022 March 31, 2022 Suntae Kim Job posting [MEDIPOST] Team Leader / Team Member – Global Regulatory Affairs (Pangyo, Korea ) We are looking for a self-motivated individual to join our … egulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma ( without age limit) ”. To date, over 21,000 patients have been treated on the market with an excellent long-term safety and efficacy profile. CARTISTEM® has also successfully completed the Phase I/II trial in the U.S. and the … rea Institute of Science and Technology )에서 application form을 영문화하여 준비하고 있습니다. (아직 일부 한글 항목이 있어, 추가 영문화 작업 중입니다.) ○ 주요일정 전형절차 시기(예정 비고 채용공고·지원서 접수 ~3.18.(금) 서류심사 4월 중순 5배수 선발 인성검사 / 자질검증세미나 5월 초순 3배수 선발 종합면접 5월 하순 신원조사 및 채용신체검사 6월 초순 ○ Rising Star 채용 – 공고문 내의 AI·로봇부문 “Rising Star” (분야구분 중 03-2)는 채용되면 초기에 독일 자르브뤼켄(Saarbruecke
%PDF-1.7 %���� 1 0 obj >/Metadata 3980 0 R/ViewerPreferences 3981 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 24 0 R] /MediaBox[ 0 0 720 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}[�fGnݻ����i#:��0 x.6&�Ď�$A ��� I�l#�>E�EV��[�1 �%{h r ɪb�"���_������? ���c��M�s��ײ4��2�o�Q_�?ބQ^G�>��C�ҕʠry|@�ƪD�0� 5^{��d���W��2W��)��l-J���V\��E}��2 �hJ���Q�����"V�JR*�;۬Ύ�*��:��"j��*ߗ ���ڢ ��י�!��P5+U�R�-�N�t ���:W�=�.�c��1�Xu(���Z=�0uɫ��]� *Z/�a�AyX�( vYd�]n �'��(����0m������j� �n��� … oyЧ e��r��Y������� ������gPԍUIw5��?�̅X� n�9ݠ���͆4��4��匈�)���A�8���)*rfp���u��f\G�P ��"vSw�5|^��[�#��i�Щk%~/��K]�.�t�㬢�нlr-9R}���xN~��QT��8�+� _g����-��s!��&�T�����R- �� #�/,&�>L)�� b�]t�٩��t�|�ʞ K�@Z-@|���f�������հ�>�F*p��6 sv�ਫ਼� �v�F|�����О J�� �A���u*\e��/��� [A1�wa��� �a$]�,T[�%*��|��dqY R�ԁ�� �U�,� ��\\�6���^Tt��y�"� �� R [e����wu��YZ������e�4J ��%dHƢ�Ku�v�X�X��Q0 �]���蜠�e��Z� bW�;Z�2g�gmi�g��������y_��#�����`��D6���)�^�� … Vgbiu�Z0�VUMC�y�eU��/-+��0��-ɗUe+,��|��jb�?-�@��2�,i��%�� Q���A�t�m S�+�rfp�S����������8�ep�B�ٵ�lO�=�p��7���YGfW/'��� �-C�K �P� %�F��O!��r=*����ĕ� �J#�����#Zh]e�g��˩U���΄��+��#�˗N�>� )�9ڀve"�V��w�c�� 2�9 �g(���n){v9Z���ڂ�Г�� ���:�+*�*�Ae+*�(J&6�QW�� U�� ��K��!f=�]0{S-~:5���!d|�@� �a���A�%+���Ub6�fsOg��� c92�9>9������̪�lF�hF������3�9��!�� ;�u���]� ڱ�9�ﲮĸ�4D]�l���b�;6 ��uY�;��Oe6���Ҷ�� ĠFf��h�}�Zbg��4��h�F�M��6 �j��7m���y.�`K�FkT
Medipost Pharmacy - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Pa
Medipost - Multiples.vc - Public Comps and Valuation Multiples Proprietary AI analyst is now available Use Cases Coverage Insights Pricing API Sign In Start Free Trial Toggle menu Public Comps Medipost Medipost Valuation Multiples Discover revenue and EBITDA valuation multiples for Medipost and similar public comparables like Protara Therapeutics , Adimmune , Tetratherix , Nextbiomedical Co and more. Start Free Trial See companies similar to Medipost Jump to Section Overview Financials Stock Performance Valuation Multiples Margins & Growth Rates Operational KPIs Public Comparables Funding … o Equity Partners, both private equity firms focused on high-tech companies, to fund entry into the North American market, including a CDMO partnership for cell and gene therapy and US clinical trials. Skylake and Crescendo, becoming MEDIPOST's largest shareholders, participated with an investment philosophy emphasizing mutual growth in overseas markets; this marked their first biotech investment. Sources describe the deal variably as securing $140 million funding, acqui … y the same investors plus Woori Private Equity and NH Private Equity to further fund ongoing trials, and an additional KRW 71.8 billion rights offering post-2022. In March 2022, Crescendo and Skylake jointly acquired the firm for approximately 160 billion won. MEDIPOST completed first dosing of Cartistem in Japan's Phase 3 trial subsequently. Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples Sign up to see data on 350K+ funding rounds and disclosed reve … a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs around 7,00 people. Edwards Lifesciences Spun off from Baxter International in 2000, Edwards Li … ay. Subscribe Use Cases VC & PE Investment Banks Corporate Development CFOs Fund Service Providers API Coverage Data Sectors We Cover Tech Themes Free Valuation Tools Sector Indexes Public Comps Database Valuation Multiples by Sector Resources Industry Reports Newsletter Download Our Deck Refer and Earn Company Start Free Trial Pricing Email
osteoarthritis – Page 3 – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO Inquiries
Medipost to set up CDMO subsidiary 주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기 잠깐! 현재 Internet Explorer 8이하 버전을 이용중이십니다. 최신 브라우저(Browser) 사용을 권장드립니다! ie 인터넷 익스플로러 11 다운로드 chrome 구글 크롬 다운로드 firefox 모질라 파이어폭스 다운로드 상단영역 UPDATE : 2026-06-25 16:02 (Thurs) Home Log in Join 전체메뉴 기사검색 검색 본문영역 이전 기사보기 다음 기사보기 Medipost to set up CDMO subsidiary 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 스크롤 이동 상태바 현재위치 Home Bio Medipost to set up CDMO subsidiary 기자명 Kim Chan-hyuk Published 2022.05.25 12:02 Comments 0 --> 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 SNS 기사보내기 Facebook(으)로 기사보내기 Twitter(으)로 기사보내기 Kakaostory(으)로 … forming Biosplice drug in animal tests Comments Log In 작성자 비밀번호 댓글 내용입력 0 / 400 Submit 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More Delete comments Deleted comments cannot be recovered. Do you still want to delete it? Password Delete 닫기 Modify the comments You can modify comments only within 1 minute after writing. Text / 400 Password Modify 닫기 My comme
MEDIPOST CEO shares journey to US market with stem cell therapy case study | MEDIPOST Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
BDA advises MEDIPOST on growth capital raise - BDA Partners Search for: English 日本語 简体中文 한국어 Contact Careers Alumni About us Team Our Services Sectors Chemicals Consumer & Retail Health Industrials Services Sustainability Technology Financial Sponsors Transactions News & Insights Contact Us Careers Experienced professionals Students & graduates Alumni English 日本語 简体中文 한국어 Search for: 18 December 2025 BDA advises MEDIPOST on growth capital raise raised capital from 2025 BDA Partners is pleased to announce that its client MEDIPOST, a leading stem cell therapeutics & cord blood … rials in the US and Japan. The proceeds from this capital raise will be used to fund the ongoing clinical trials. In 2022, Skylake Equity Partners and Crescendo Equity Partners acquired a control stake in the Company. Howard Lee, Partner and Head of BDA, Seoul, said: “We’re delighted to have advised MEDIPOST on this growth capital raise. Despite the inherent regulatory and development complexities in the stem cell therapeutics sector, this transaction demonstrates that compan
CDMO Service – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO Inquiries IR Inquiries CDMO
MEDIPOST reports Q1 operating profit on Cartistem deal | THE BIO (더바이오) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr
OmniaBio, Medipost Ink Acquisition and Investment Deal | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe Now Stay infor
COMPANY – MEDIPOST LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO Inquiries IR Inquiries About Us … m cell platform technology. Awarded ‘2016 Frost & Sullivan Korea Excellence Award’ (2016) Conducted investigator-initiated clinical trial of PNEUMOSTEM ® for the treatment of Intra-Ventricular Hemorrhage(IVH) in premature infants (2016) Completed 5-year follow-up of Phase 3 clinical trial patients who received CARTISTEM ® treatment (2016) Awarded the ‘Excellent Workplace for Women’ award in Gyeonggido Korea (2016) Achieved commercial sale of 5,000 cumulative doses of CART … eoarthritis(OA) in Korean market (2017) Awarded the ‘Family-Friendly Workplace’ Award by the Ministry of Gender Equality and Family Korea (2017) Successfully completed Phase 1/2 (US-FDA) clinical trial of CARTISTEM ® for the treatment of patients with knee cartilage defects in the U.S. (2018) Achieved commercial sale of 10,000 cumulative doses of CARTISTEM ® for the treatment of knee articular cartilage defects and Osteoarthritis(OA) in Korean market (2018) Cleared Phase 1/2 … orea for the treatment of Alzheimer’s Disease (2012) Received Biologics License Application(BLA) market-authorization of CARTISTEM ® in Korea – world’s first regulatory approval of allogeneic stem cell product, for the treatment of degenerative Osteoarthritis (2012) Achieved first export of stem cell product – CARTISTEM ® from Korea to Hong Kong (2012) Selected as ‘Outstanding Achiever with Government R&D Support’ by the National Research Council of Science & Technolo … sia(BPD) was designated as ‘Orphan Drug’ by the US-FDA (2013) Awarded the Grand Prize (MFDS Minister’s Award) at the inaugural ‘Korea New Drug Award’ Korea (2013) New Pangyo headquarter was established with CELLTREE ® cord blood bank and R&D Center at the Pangyo Techno Valley, Gyeonggi-do Korea (2014) Cleared Phase 1/2 clinical trial (Investi
MEDIPOST – The Future of Biotechnology LANGUAGE KOREAN ENGLISH LOCATION COMPANY R&D R&D Institute GMP Center Clinical Development Status Publications PRODUCTS 1st Generation Overview CARTISTEM ® PNEUMOSTEM ® 2nd Generation Overview SMUP-IA-01 SMUP-IV-01 R&D Inquiries BUSINESS CDMO Quality System CDMO Service Quality Control Global CDMO CDMO Inquiries CELLTREE Cord Blood Bank MOVITA Nutritional Supplements IR Stock Information Disclosure Financial Information IR Inquiries PR MEDIPOST on Media Corporate Brochure CONTACT US Customer Center R&D Inquiries CDMO Inquiries IR … STEM® Reaches Milestone of treating 30,000 Patients 2024/06/24 MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle In… 2023/12/27 MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billi… 2023/10/04 MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery… 2023/05/02 VIEW MORE NEWS Global Leader in Stem Cell Therapeutics 93+ 0 + Number of registered patents in Korea and overseas 38+
間葉性肝細胞分化に及ぼす心筋梗塞蛋白質と振動圧の衝撃:幹細胞分化に及ぼす急性心筋梗塞の影響 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター 文献 J-GLOBAL ID：200902210197225773 整理番号：08A0853934 間葉性肝細胞分化に及ぼす心筋梗塞蛋白質と振動圧の衝撃:幹細胞分化に及ぼす急性心筋梗塞の影響 Impact of Myocardial Infarct Proteins and Oscillating Pressure on the Differentiation of Mesenchymal Stem Cells: Effect of Acute Myocardial Ionfarction on Stem Cell Differentiation 出版者サイト 複写サービスで全文入手 {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=08A0853934&COPY=1") }} このテーマを更に深掘りする（JDreamⅢへ） {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=08
MEDIPOSTs Cartistem Enters US Phase 3 Clinical Trial | THE BIO (더바이오) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
US8614191B2 - Use of ICAM-1 for prevention or treatment of neurological diseases - Google Patents US8614191B2 - Use of ICAM-1 for prevention or treatment of neurological diseases - Google Patents Use of ICAM-1 for prevention or treatment of neurological diseases Download PDF Info Publication number US8614191B2 US8614191B2 US13/365,022 US201213365022A US8614191B2 US 8614191 B2 US8614191 B2 US 8614191B2 US 201213365022 A US201213365022 A US 201213365022A US 8614191 B2 US8614191 B2 US 8614191B2 Authority US United States Prior art keywords icam protein disease another embodiment fragment Prior ar … is and makes no representation as to the accuracy of the status listed.) Active Application number US13/365,022 Other versions US20120196809A1 ( en Inventor Yoon-Sun Yang Won Il OH Jong Wook Chang Ji Hyun Kim Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Medipost Co Ltd Original Assignee Medipost Co Ltd Priority date (The priority date is an assumptio … sted.) 2011-02-02 Filing date 2012-02-02 Publication date 2013-12-24 2012-02-02 Application filed by Medipost Co Ltd filed Critical Medipost Co Ltd 2012-02-02 Priority to US13/365,022 priority Critical patent/US8614191B2/en 2012-02-03 Assigned to MEDIPOST CO., LTD. reassignment MEDIPOST CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANG, JONG WOOK, KIM, JI HYUN, OH, WON IL, YANG, YOON-SUN 2012-08-02 Publication of US20120196809A1 publicati … on of US20120196809A1 publication Critical patent/US20120196809A1/en 2013-12-24 Application granted granted Critical 2013-12-24 Publication of US8614191B2 publication Critical patent/US8614191B2/en Status Active legal-status Critical Current 2032-02-02 Anticipated expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE … s placed in a nasal administrator designed to deliver 100 ⁇ l of spray for each application. a 0.05M phosphate buffer solution pH 4.4 Landscapes Health & Medical Sciences ( AREA ) Life Sciences & Earth Sciences ( AREA ) Engineering & Computer Science ( AREA ) Bioinformatics & Cheminformatics ( AREA ) Medicinal Chemistry ( AREA ) V